Clovis and Clavis extend cancer deal including Asian rights
This article was originally published in Scrip
Executive Summary
Clovis Oncology has tightened its control over Oslo-based Clavis Pharma's Phase II pancreatic cancer treatment CP-4126 by extending its development and commercialisation rights into Asia and the rest of the world.